This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.




2gfc

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2gfc.gif|left|200px]]
+
{{Seed}}
 +
[[Image:2gfc.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2gfc| PDB=2gfc | SCENE= }}
{{STRUCTURE_2gfc| PDB=2gfc | SCENE= }}
-
'''cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24'''
+
===cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24===
-
==Overview==
+
<!--
-
Controlling aberrant kinase-mediated cellular signaling is a major strategy in cancer therapy; successful protein kinase inhibitors such as Tarceva and Gleevec verify this approach. Specificity of inhibitors for the targeted kinase(s), however, is a crucial factor for therapeutic success. Based on homology modeling, we previously identified four amino acids in the active site of Rho-kinase that likely determine inhibitor specificities observed for Rho-kinase relative to protein kinase A (PKA) (in PKA numbering: T183A, L49I, V123M, and E127D), and a fifth (Q181K) that played a surprising role in PKA-PKB hybrid proteins. We have systematically mutated these residues in PKA to their counterparts in Rho-kinase, individually and in combination. Using four Rho-kinase-specific, one PKA-specific, and one pan-kinase-specific inhibitor, we measured the inhibitor-binding properties of the mutated proteins and identify the roles of individual residues as specificity determinants. Two combined mutant proteins, containing the combination of mutations T183A and L49I, closely mimic Rho-kinase. Kinetic results corroborate the hypothesis that side-chain identities form the major determinants of selectivity. An unexpected result of the analysis is the consistent contribution of the individual mutations by simple factors. Crystal structures of the surrogate kinase inhibitor complexes provide a detailed basis for an understanding of these selectivity determinant residues. The ability to obtain kinetic and structural data from these PKA mutants, combined with their Rho-kinase-like selectivity profiles, make them valuable for use as surrogate kinases for structure-based inhibitor design.
+
The line below this paragraph, {{ABSTRACT_PUBMED_16699172}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 16699172 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_16699172}}
==About this Structure==
==About this Structure==
Line 31: Line 35:
[[Category: Binary complex]]
[[Category: Binary complex]]
[[Category: Peptide inhibitor]]
[[Category: Peptide inhibitor]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 05:02:30 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 00:02:58 2008''

Revision as of 21:03, 27 July 2008

Image:2gfc.png

Template:STRUCTURE 2gfc

cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24

Template:ABSTRACT PUBMED 16699172

About this Structure

2GFC is a Protein complex structure of sequences from Bos taurus. Full crystallographic information is available from OCA.

Reference

Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity., Bonn S, Herrero S, Breitenlechner CB, Erlbruch A, Lehmann W, Engh RA, Gassel M, Bossemeyer D, J Biol Chem. 2006 Aug 25;281(34):24818-30. Epub 2006 May 12. PMID:16699172

Page seeded by OCA on Mon Jul 28 00:02:58 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2gfc"
Personal tools